61-70 of 79 results
Government rejigs electronic health records system with opt-out approach
The Federal Governments electronic health records system may have a new lease on life following the introduction of a new Bill that attempts to improve the systems effectiveness with key changes such as the transition to an opt-out approach Partner Ian McGill Senior Associate Phil OSullivan and ...
Protecting innovation without patents - data exclusivity and market exclusivity
Developments in patent law and the consequential limitations on patentability for biologic medicines mean that data exclusivity and market exclusivity can be the primary protection afforded to originator biologic medicines This is most stark in the US where patent protection for biologic medicines ...
Predictive coding: the future of electronic document production?
A recent decision of the English High Court may pave the way for the use of predictive coding in large scale discovery and regulatory investigations in Australia Partners Nick Rudge and Duncan Travis Managing Associate Kate Austin and Associate Emily Giblin look at the benefits and risks of the new ...
Patent examination guidelines in the wake of Myriad
Following public consultation on proposed examination guidelines issued on 16 October 2015 the Commissioner of Patents has established a revised examination practice taking into account the High Courts decision in emDArcy v Myriad Genetics Incem Dr Trevor Davies Partner at Allens Patent amp Trade ...
Not quite business as usual - IP Australia takes pragmatic view of Myriad
IP Australia has taken a pragmatic approach to the Myriad decision that will give comfort to Australias biotechnology industry and research organisations that they can continue to carry out biological RD and be able to obtain patent protection for innovation in Australia Partner Dr Trevor Davies ...
Isolated genetic material confirmed as patentable
In a unanimous decision the Full Federal Court has confirmed that genetic materials in their isolated form remain patentable in Australia The decision related to an appeal from an earlier Federal Court decision in which it was found isolated nucleic acids to be a manner of manufacture as required by ...
The ending point for 'starting point'
The Full Federal Court has published its much-anticipated judgment in the AstraZeneca v Apotex appeal A bench of five judges heard the appeal in contrast to the usual three judges in order to be able to clarify or overrule if appropriate an earlier Full Court decision relating to the correct test ...
Making sense of human cell and tissue products regulation
The Therapeutic Goods Administration has released guidance on recent changes to the regulation of human cell and tissue products Special Counsel Ric Morgan and Senior Associate Tracy Lu dissect the complex regulatory framework particularly in relation to advertising ...
OAIC concludes investigation of Australian Red Cross data breach
OAIC concludes investigation of Australian Red Cross data breach where a one-off human error by a third party provider's employee led to a massive data breach that hit the Australian Red Cross Blood Service ...
Allens advises Healthscope on sale of medical centres business
Allens has advised Healthscope Limited, one of Australia's leading private healthcare operators, on the sale of its Australian medical centres business to Fullerton Health, a leading provider of ...